CompanyGraph
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
600513 · SSE · China
lhpharma.comFinancials as of FY2024–FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.45%Below 5Y avg (1.19%)
Annual Rate
CNY 0.07Paid annual
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Jul 8, 2026
The reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2024, balance sheet FY2025, cash-flow statement FY2024. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
4.39BCNY655.61M · vs all stocks (USD)
Revenue (TTM)
3.00BCNY447.59M · vs all stocks (USD)
Profit Margin
-1.59%Beta
-0.2310xvs all stocks
52-Week Change
-20.68%vs all stocks
Market Capitalization
4.39BCNY655.61M · vs all stocks (USD)
Enterprise Value
6.07BCNY906.11M · vs all stocks (USD)
Price to Sales (TTM)
1.46xPrice to Book (MRQ)
3.45xEnterprise to Revenue
2.02xEnterprise to EBITDA
59.94xGross Margin
30.97%Profit Margin
-1.59%Operating Margin
2.72%Return on Assets (TTM)
-0.18%Return on Equity (TTM)
-2.21%Revenue (TTM)
3.00BCNY447.59M · vs all stocks (USD)
Revenue per Share (TTM)
10.79CNYUpdated Sep 21, 2026Quarterly Revenue Growth
15.60%Gross Profit (TTM)
885.09MCNY132.17M · vs all stocks (USD)
EBITDA (TTM)
194.28MCNY29.01M · vs all stocks (USD)
Net Income (TTM)
-47.78MCNY-7.14M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
47.36%Operating Cash Flow (TTM)
58.72MCNY8.77M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-146.80MCNY-21.92M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0700CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.45%vs all stocks
5-Year Average Dividend Yield
1.19%vs all stocks
Payout Ratio
0.00%Revenue
2.16BCNYFY2024 · Dec 31, 2024Cost of Goods Sold
1.09BCNYFY2024 · Dec 31, 2024Gross Profit
1.07BCNYFY2024 · Dec 31, 2024Operating Income
143.39MCNY21.41M · vs all stocks (USD)
Pre-tax Income
130.43MCNYFY2024 · Dec 31, 2024Income Tax Expense
24.01MCNYFY2024 · Dec 31, 2024Net Income
106.41MCNYFY2024 · Dec 31, 2024EBIT
155.38MCNYFY2024 · Dec 31, 2024EBITDA (Income Statement)
194.28MCNYFY2024 · Dec 31, 2024Research & Development
154.59MCNYFY2024 · Dec 31, 2024Selling, General & Administrative
638.30MCNYFY2024 · Dec 31, 2024Other Operating Expenses
19.74MCNYFY2024 · Dec 31, 2024Non-operating Interest Income
1.16MCNYFY2024 · Dec 31, 2024Non-operating Interest Expense
24.95MCNYFY2024 · Dec 31, 2024EPS (Basic)
0.2900CNYFY2024 · Dec 31, 2024EPS (Diluted)
0.2900CNYFY2024 · Dec 31, 2024Basic Shares Outstanding
290.21MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
290.21MSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
106.41MCNYFY2024 · Dec 31, 2024Minority Interests (P&L)
-22.25MCNYFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00CNYFY2024 · Dec 31, 2024Operating Cash Flow
-60.71MCNYFY2024 · Dec 31, 2024Free Cash Flow
-245.55MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
186.69MCNYFY2024 · Dec 31, 2024Starting Profit (CF Statement)
106.41MCNYFY2024 · Dec 31, 2024Other Non-cash Items
25.74MCNYFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-60.14MCNYFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
-132.74MCNYFY2024 · Dec 31, 2024Capital Expenditures
-184.84MCNYFY2024 · Dec 31, 2024Purchase of Investments
-22.00MCNYFY2024 · Dec 31, 2024Sale of Investments
22.01MCNYFY2024 · Dec 31, 2024Net Investing Cash Flow
-184.83MCNYFY2024 · Dec 31, 2024Long-term Debt Issuance
847.98MCNYFY2024 · Dec 31, 2024Long-term Debt Payments
-673.49MCNYFY2024 · Dec 31, 2024Common Dividends Paid
-50.57MCNYFY2024 · Dec 31, 2024Other Financing Charges
-10.22MCNYFY2024 · Dec 31, 2024Net Financing Cash Flow
113.71MCNYFY2024 · Dec 31, 2024Shares Outstanding
285.46MSharesUpdated Sep 21, 2026Float Shares
167.82MSharesUpdated Sep 21, 2026% Held by Insiders
43.70%vs all stocks
% Held by Institutions
0.67%vs all stocks
Total Cash (MRQ)
285.84MCNY42.68M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.00CNYUpdated Sep 21, 2026Total Debt (MRQ)
1.71BCNY255.43M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.03xCurrent Ratio (MRQ)
0.9270xBook Value per Share (MRQ)
4.46CNYUpdated Sep 21, 2026Cash Equivalents
71.18MCNYFY2025 · Dec 31, 202552-Week Low
13.67CNYUpdated Sep 21, 202652-Week High
32.27CNYUpdated Sep 21, 202652-Week Change
-20.68%vs all stocks
Beta
-0.2310xvs all stocks
50-Day MA
16.44CNYUpdated Sep 21, 2026200-Day MA
18.99CNYUpdated Sep 21, 2026Avg 10-Day Volume
6.23MSharesUpdated Sep 21, 2026Avg 30-Day Volume
12.68MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.1600CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nuvectis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kinetic Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Senores Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xiangxue Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hvsen Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Climb Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Contec Medical Systems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow